A Post-Marketing Surveillance Study to Evaluate the Safety and Effectiveness of Sovaldi in Patients With Chronic Hepatitis C Virus (HCV) Infection in Korea
Latest Information Update: 30 Dec 2021
At a glance
- Drugs Sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- Sponsors Gilead Sciences
- 23 Dec 2021 Status changed from active, no longer recruiting to completed.
- 29 Sep 2021 Status changed from recruiting to active, no longer recruiting.
- 12 May 2021 Planned End Date changed from 1 Sep 2021 to 1 Dec 2021.